News | Vascular Access | September 20, 2016

Teleflex Promotes Rise of the Vascular Access Specialist at AVA 2016 Congress

Company features new online clinical education platform, hosts several symposia on vascular access technology

Teleflex, AVA 2016 Congress, Association for Vascular Access

September 20, 2016 — Teleflex Inc. recently displayed its vascular access technologies and a new educational platform focused on the rise of the vascular access specialist at the 30th Annual Scientific Meeting of the Association for Vascular Access (AVA). The meeting was held Sept. 16-19 in Orlando, Fla.

Teleflex unveiled the Teleflex Academy, a new online clinical education platform. The booth educational experience for the Teleflex Academy at this year’s AVA focused on every aspect of vascular access. Teleflex believes that quality education is the first step in fostering the expansion of skills and helping to shape clinical practice.

Teleflex also launched the Arrow Midline with Chlorag+ard Technology, adding to the family of antithrombogenic and antimicrobial protected catheters.

The company offered its popular Vascular Access Procedural Cadaver Lab onsite, training on many different vascular access procedures. There were also clinical education activities at its booth, where models were used to demonstrate the full range of the company’s vascular access devices.

At the breakfast symposium, “Rising to the Challenge: How Vascular Access Specialists Started Placing CVCs,” attendees were educated on the importance of the evolution of the vascular access specialist. This course highlighted the experiences of clinicians who have made the journey to expand their roles to place central venous catheters, and described the clinical process and materials needed to develop a vascular access team.

The platinum showcase symposium, “Locking the Lumen…Consider the Solutions!” reviewed why given today’s medical reimbursement risks, facilities must explore all opportunities to reduce potential vascular access complications. Locking solutions could provide an additional layer of protection when used in conjunction with proven protected catheter technology. The presentation addressed catheter colonization, intraluminal colonization, and how locking solutions and protected catheters address these.

The dinner symposium, “Strategy or Risk: the Use of Midline Catheters”, focused on the recent popularity of Midline catheters, the role of a Midline, and how technology could be the key to ensuring Midline success.

For more information:

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init